Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

"What Must EPS Pilot Prove?" Asks NPA
The NPA is asking its members to utilise the new NPA IT forums website to comment on the criteria that should be used to demonstrate that EPS is operationally functional ahead of national roll-out. The NPA believes that EPS must work technically, be business and operationally functional, improve service delivery at pharmacies, and is safe for patients, before full roll-out can be contemplated. The website, http://itforums.npa.co.uk, provides an opportunity for members throughout the UK to voice their opinions on the IT programmes affecting their country or on general IT topics which affect all nations. Don't forget to buy zoloft online no prescription.

Risk Of Heart Failure Doubled By Obesity And Diabetes -- Patients With Both Conditions 'Very Difficult' To Treat
The twin epidemics of obesity and type 2 diabetes will continue to fuel an explosion in heart failure, already the world"s most prevalent chronic cardiovascular disease, according to John McMurray, professor of cardiology at the Western Infirmary, Glasgow, and President of the Heart Failure Association. He reported that around one-third of patients with heart failure have evidence of diabetes, and for them the outlook is very serious. For doctors, he added, effective treatment is "very difficult".

generic viagra online


News of the day
Facing Congressional Squabbling, President Pushes For Reform
The press for health care reform hit a snag this week as Congress sputtered to resolve its differences, but President Barack Obama continues his call, almost daily, to continue to try to change the system, The New York Times reports.
Sexual Health

Upcoming BioAlliance Pharma's Presentations At International Conferences On Infectious Diseases And Oncology

BioAlliance Pharma SA (Paris:BIO), a company dedicated to therapies and supportive care for cancer and AIDS patients, announced its scientific communications at upcoming international conferences on infectious diseases and oncology: Loramyc®, indicated for fungal infections in immune-compromised patients with HIV or cancer The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 to June 2, 2009 - Orlando, Florida, USA. Abstract: "Prevalence and management of oropharyngeal candidiasis (OPC) by medical and radiation oncologists in cancer patients". At the American Conference for the Treatment of HIV (ACTHIV) that took place on May 15-17, 2009 in Denver, Colorado, USA, BioAlliance Pharma presented the poster: "Once-Daily Miconazole Mucoadhesive Buccal Tablet is an Effective and Safe Treatment for Oropharyngeal Candidiasis". Amep™, a biotherapy for Metastatic Melanoma treatment American Society of Gene Therapy (ASGT) 12th Annual Meeting May 27-30, 2009 - San Diego, California, USA Poster: "Complete Melanoma Regressions after Electrotransfer of the p-AMEP™ Plasmid Coding for an Anti-Angiogenic and Anti-Metastatic Peptide", May 28. Anti-integrases: new antiretroviral drugs for the treatment of resistant HIV-1 XVIII International HIV Drug Resistance Workshop June 9-13, 2009 - Fort Myers, Florida, USA Oral communication and poster: "New integrase binding inhibitors acting in synergy with Raltegravir", June 12. Irinotecan SRN oral formulation for the treatment of advanced colorectal cancer 2nd Pharmaceutical Sciences Fair and Exhibition (PharmSciFair) June 8-12, 2009, Nice, France Oral communication: "Sustained Release Nanoparticles (SRN) for oral administration of Irinotecan", June 10. BioAlliance Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009